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esponsibility of InstAbstract The aim of this study was to characterize the provesicle formulation of nateglinide (NTG) to
facilitate the development of a novel controlled release system of NTG with improved efﬁcacy and oral
bioavailability compared to the currently marketed NTG formulation (Glinate™ 60). NTG provesicles
were prepared by a slurry method using the non-ionic surfactant, Span 60 (SP), and cholesterol (CH) as
vesicle forming agents and maltodextrin as a coated carrier. Multilamellar niosomes with narrow size
distribution were shown to be successfully prepared by means of dynamic laser scattering (DLS) and ﬁeld
emission scanning electron microscopy (FESEM). The absence of drug-excipient interactions was
conﬁrmed by Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC)
and X-ray diffraction (XRD) studies. In vitro release of NTG in different dissolution media was improved
compared to pure drug. A goat intestinal permeation study revealed that the provesicular formulation (F4)
with an SP:CH ratio of 5:5 gave higher cumulative amount of drug permeated at 48 h compared to
Glinate™ 60 and control. A pharmacodynamic study in streptozotocin-induced diabetic rats conﬁrmed
that formulation F4 signiﬁcantly (Po0.05) reduced blood glucose levels in comparison to Glinate 60.
Overall the results show that controlled release NTG provesicles offer a useful and promising oral delivery
system for the treatment of type II diabetes.
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Since the 1980s, non-ionic surfactant vesicles (niosomes) have
been shown to possess distinct advantages over conventional
dosage forms and play an increasingly important role in drug
delivery. Compared to phospholipids, nonionic surfactants form
vesicles that are more stable, easier to handle and less expensive to
produce1. In recent years, provesicular (proniosomal) derived
niosomes have received considerable attention as an oral dosage
form with the potential to improve therapeutic activity, reduce side
effects and enhance stability of drugs to chemical degradation or
transformation. This is because niosomes themselves have limita-
tions for oral delivery due to poor integrity at the site of
absorption, physicochemical instability to hydrolysis, separation
of drug and their tendency to sediment and aggregate1,2.
A proniosomal formulation is a dry formulation of a liquid
crystalline niosomal hybrid which converts to niosomes upon
hydration with aqueous media. It offers a versatile drug delivery
system that is not only capable of encapsulating drug but can also
minimize drug degradation after administration, prevent undesir-
able side effects and increase drug bioavailability3–5. In addition, it
is convenient to transport, distribute and store and less subject to
the high cost and variable purity problems of phospholipid based
formualtions6. All this makes proniosomes (or ‘dry niosomes’) a
promising, commercially valuable product2.
Nateglinide [N-(trans-4-isopropylcyclohexylcarbonyl)-D-pheny-
lalanine, NTG] is a novel non-sulfonylurea oral hypoglycemic
agent which has outstanding clinical effectiveness in the treatment
of type II diabetes mellitus. Its mechanism of action involves
increasing insulin release from pancreatic β-cells through inhibi-
tion of potassium-ATP channels. After oral administration, NTG is
rapidly absorbed from the gastrointestinal tract and rapidly
eliminated from plasma with a half-life of approximately 1.5 h.
As a result, a dose of NTG of 20–40 mg must be administered
thrice a day. In addition, NTG has low bioavailability and poor
dose proportionality probably resulting from its limited absorption
through the gastrointestinal tract consequent on its low water
solubility (8 mg/L)7 and/or wettability8.
Maltodextrins (MLTs) are complex mixtures of high and low
molecular weight carbohydrates obtained by acid and/or enzymatic
hydrolysis of starch. They contain linear amylose and branched
amylopectin degradation products and are considered as D-glucose
polymers joined by α-(1,4) and α-(1,6) linkages. MLTs are
endowed with the capability to form complexes with various
classes of compounds usually of the host–guest type. Complex
formation depends on the size of the complexing molecule and is
believed to require a conformational change from a ﬂexible coil to
a helix form in the presence of the guest molecule9. Because NTG
probably exhibits dissolution rate limited absorption, we antici-
pated that its dissolution rate would be improved through the
preparation of an MLT complex. The aim of this study was
therefore to examine a provesicular system based on the MLT
complex of NTG.
MLT-based provesicular powders offer a simple and stable
carrier for efﬁcient oral delivery of lipophilic or amphiphilic drugs
since they allow the production of provesicles with greater drug
loading. Due to its high surface area and porous structure, MLT
forms provesicles with high surfactant:carrier mass ratios10. MLT-
based NTG provesicles prepared with the nonionic surfactant Span
60 (SP) have been previously reported9,11. SP with its longer
saturated alkyl chains and high phase transition temperature shows
higher entrapment efﬁciency (EE) in comparison with those ofother nonionic surfactants12–16. Cholesterol (CH) is also com-
monly included not only to improve the stability and EE of a
vesicular formulation but also to impart rigidity and orientational
order to the niosomal bilayer9,16–19.
Many formulation approaches have been investigated to
improve the bioavailability of NTG including various solvent
systems20, solid dispersions21, complexes with β-cyclodextrins22–24,
ﬂoating microspheres25,26, polymeric nanoparticles and solid lipid
nanoparticles27,28. To date, no study has evaluated an MLT-based
provesicular drug delivery system of NTG for diabetic therapy.
In this study, controlled release provesicles of NTG–MLT complex
were prepared and evaluated with the aim of producing an NTG
formulation that would provide decreased dosing frequency, fewer
side effects and increased bioavailability.2. Material and methods
2.1. Materials
NTG (purity 99.87%) was a gift from Alembic Pharmaceutical
Ltd. (Vadodara, India). A commercial sample of Glinate™-60
(Glenmark Pharmaceuticals Ltd., Mumbai, India) was procured
from a retail pharmacy. MLT and SP were purchased from Loba
Chemie (Pvt.) Ltd. (Mumbai, India). CH was obtained from Sigma
Chemical Co., India. Potassium dihydrogen phosphate, disodium
hydrogen phosphate, sodium chloride and potassium chloride were
all of analytical grade from S.D. Fine Chem. Ltd. (Mumbai, India).
All other chemicals and solvents were of analytical grade and used
as received.
2.2. Preparation of NTG–MLT provesicular powders
Provesicular powders of the NTG–MLT complex were prepared
containing different ratios of CH and SP according to a literature
method9 with slight modiﬁcations. The compositions of the NTG
provesicles are given in Table 1. In brief, 100 mg MLT was placed
into a 100 mL round-bottomed ﬂask followed by a solution of
NTG (60 mg), SP and CH (total lipid 100 mmol/L) in 10 mL
chloroform. The mixture was vortexed for 5–10 min to obtain a
slurry with additional chloroform being added in the case of
mixtures with lower surfactant loading. Chloroform was then
removed by rotary evaporation under reduced pressure at 50–
60 1C over 15–20 min. After drying, powders were placed in a
desiccator overnight to ensure complete evaporation of solvent.
The ﬁnal “provesicular powders” were stored in sealed glass
containers at room temperature until characterization.
2.3. Formation of niosomes from provesicular powders
Niosomes were prepared from provesicular powders by hydration
with phosphate buffered saline (PBS) pH 7.4 at 80 1C using a
vortex mixer for 2 min. The resultant dispersion was then
subjected to determination of particle size, zeta potential, EE and
morphology.
2.4. Characterization aspects
2.4.1. Field emission scanning electron microscopy (FESEM)
The morphology of pure NTG, blank and the optimized formula-
tion (F4) was examined by FESEM using a JSM 6360 electron
Table 1 Composition, entrapment efﬁciency (EE %) and particle size analysis of various provesicular formulations of nateglinide.
Formulation Lipid compositiona EE (%)b Mean vesicle size (nm)b PI
SP CH
F1 9 1 66.5671.41 364.9743.7 0.55
F2 7.5 2.5 71.0372.25 405.1753.1 0.49
F3 6 4 77.7371.50 382.6747.3 0.45
F4 5 5 84.7671.13 262.4776.2 0.27
F5 4 6 80.2372.20 333.2754.0 0.40
F6 2.5 7.5 74.6572.18 374.8761.2 0.49
F7 1 9 68.7171.27 331.1744.8 0.45
SP, Span 60; CH, Cholesterol; and PI, Polydispersity index.
aMolar ratio.
bData are expressed as means7SD, n¼3.
Ranjan Ku. Sahoo et al.410microscope (Jeol, UK) at an accelerating voltage of 17 kV.
A small amount of sample was placed on the FESEM holder with
double sided adhesive tape and coated with a layer of gold of
150 Å for 2 min under argon at a pressure of 0.3 atm. Each
experiment was performed in triplicate.2.4.2. Size and distribution analysis
Vesicle size (VS) and polydispersity index (PI) were determined at
25 1C by dynamic light scattering using a Zetasizer NanoZS90
analyzer (Malvern Instruments, Malvern, UK) at 901 scattering
angle. Zeta potential was measured using Laser Doppler Micro-
electrophoresis. NTG provesicular powder (2 mg) was mixed with
10 mL PBS pH 7.4 and vortexed for 3 min in a glass tube. The
dispersion was then ﬁltered through a syringe ﬁlter (0.45 mm)
before determination. PIo0.3 was taken to indicate a homogenous
and monodisperse population; PI40.3 was taken to indicate high
heterogeneity29,30. Each experiment was performed in triplicate.2.4.3. EE of niosomes
EE was determined by centrifugation to separate non-entrapped
drug from niosomes2. In this method, 1 mL aliquots of drug-
loaded niosomal dispersions were centrifuged (Remi CPR-24) at
18,000 rpm for 40 min at 4 1C. The niosomal pellet was resus-
pended in PBS pH 7.4 and then centrifuged again to ensure
removal of free drug from the void volume between niosomes.
After each centrifugation, drug content was determined in the
supernatant by UV–Vis spectrophotometry (JASCO V-560) at
210 nm using 1-cm quartz cells against PBS pH 7.4 as blank. The
amount of encapsulated drug was obtained by subtracting the
amount of free drug from the total drug added31. Each experiment
was carried out in triplicate. EE (%) is calculated as follows:
EE ð%Þ ¼Amount of drug entrapped
Total amount of drug
 100% ð1Þ2.4.4. Osmotic shock studies
The effect of osmotic shock on niosome formulations was
investigated by measuring the change in VS following incubation
of vesicular suspensions in media of different tonicities32,33.
A hypertonic medium was simulated using 1 mol/L sodium iodide
solution; isotonic medium was normal saline (0.9% NaCl);
hypotonic medium was 0.5% NaCl. Vesicular suspensions were
incubated in these media for 3 h before VS was measured.2.4.5. Fourier transform infrared (FTIR) spectroscopy
FTIR spectra of pure NTG, blank and F4 formulations were
recorded in KBr discs using a Jasco FTIR spectrophotometer
(Model FTIR-4100, Jasco, USA) to examine interactions between
drug and excipients. FTIR measurements were performed at
ambient temperature at a constant resolution of 0.9 cm1 in the
scanning range 4000–500 cm1.2.4.6. Differential scanning calorimetry (DSC)
The physical state of NTG (whether crystalline or amorphous) in
provesicular powders was investigated by DSC using a Perkin-
Elmer differential scanning calorimeter (Model Pyris Diamond,
DSC, USA). Samples were placed in ﬂat bottomed aluminum pans
and heated from 35 to 350 1C using a platinum crucible and alpha
alumina powder as reference material. Heat ﬂow rate was kept at
12 1C/min with a nitrogen stream at 20 mL/min.2.4.7. X-ray diffraction (XRD)
XRD analysis was conducted using an Ultima IV Multipurpose
X-ray diffractometer (Rigaku, Japan). The samples were measured
with a Cu targeted, nickel ﬁltered, graphite diffracted beam
monochromator using 40 kV voltage and 30 mA current. The rate
of scanning was 1 1/min over a diffraction angle of 2θ in the range
3–451.2.5. In vitro release
The release of NTG from provesicular powders was determined in
HCl (pH 1.2) and PBS, pH 7.4 using a vertical Franz diffusion
cell. The receptor compartment contained 100 mL dissolution
medium maintained at 3770.5 1C by means of a thermostatically
controlled water bath and magnetic stirring at 50 rpm. Aliquots
(1 mL), after 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24, 36 and 48 h using
a syringe, were ﬁltered through 0.2 mm membrane ﬁlter and
determined by UV–Vis spectrophotometry (JASCO V-560) at
210 nm. Each sample was replaced with fresh medium to maintain
sink conditions. Dissolution experiments were carried out in
triplicate. In order to understand the barrier effect of the dialysis
membrane, in vitro release of NTG from the same amount of pure
NTG was investigated in the same way. Release data were
evaluated according to zero order, ﬁrst order and Higuchi diffusion
models34. The correlation coefﬁcients (r) of the ﬁts were subjected
to statistical evaluation using ANOVA at 5% level of signiﬁcance.
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An intestinal permeation study was performed using a vertical Franz
diffusion cell with an effective diffusion area of 3.14 cm2. The
experiment was carried out using mucosal sheets of freshly killed
goat intestine obtained from the local slaughterhouse and stored at
18 1C. Intestines wereﬁrst ﬂushed with physiological solution at
room temperature for 2 h to remove any intestinal contents35. A
circular piece of intestine about 3 cm diameter was then threaded into
the donor compartment of the vertical diffusion chamber and 2 mL
drug loaded with niosomal dispersion was added to the mucosal side
and sealed with Paraﬁlm. The receptor compartment was ﬁlled with
25 mL PBS pH 7.4 , maintained at 37.570.5 1C and magnetically
stirred to prevent any boundary layer effects. Aliquots (1 mL) were
withdrawn from the receptor compartment after 0.25, 0.5, 0.75, 1, 2,
4, 6, 8, 12, 24, 36 and at 48 h, each withdrawal being immediately
replaced with fresh PBS to maintain sink conditions. Drug content of
samples was analyzed by UV–Vis spectrophotometry (JASCO V-
560) at 210 nm. Permeation studies of NTG from Glinate 60 and pure
NTG (control) were also investigated in the same way. Each
experiment was performed in triplicate.
2.6.1. Calculation of permeation parameters
The permeation proﬁles of NTG through goat intestine were
constructed by plotting the total cumulative amount of drug
permeated per unit surface area (dM/A mg/cm2) versus time t (h).
NTG steady state ﬂux, Jss (mg/cm
2/h) is calculated as the slope of
the linear regression line36.
Jss ¼
dM
Adt
ð2Þ
The permeability coefﬁcient (Kp) is calculated using the relation
derived from Fick's ﬁrst law of diffusion as follows:
Kp ¼
Jss
C0
ð3Þ
where C0 is the initial drug concentration in the donor compartment.
The enhancer ratio (Er) is also calculated from the following
equation:
Er ¼
Jenh
Jctrl
ð4Þ
where Jenh is the ﬂux from the formulation and Jctrl is the ﬂux of
drug from control (pure NTG)3.
2.7. Stability study
Provesicular powder formulations were packed and sealed in
amber glass vials and subjected to stability studies as per ICH
guidelines and kept in refrigerator (2–8 1C) and room temperature
(2572 1C) for a period of 3 months37. Samples were withdrawn
and hydrated with PBS after 1, 2 and 3 months and examined for
any drug precipitation by optical microscopy. The EE and mean
VS of each sample were determined and compared to freshly
prepared provesicular formulations. Each experiment was per-
formed in triplicate. Samples are also evaluated for retention of
NTG which is calculated as
Retention of NTG ð%Þ ¼ Entrapped NTG after storage
Entrapped NTG before storage
 100
ð5Þ2.8. Pharmacodynamic study
Male Wistar albino rats (age 8 weeks; weight 180–200 g) were
kept in clean polypropylene cages and maintained at 25 1C under a
dark/light cycle (12 h/12 h) for 10 days prior to the experiment.
Standard laboratory diet and water were provided ad libitum. The
animal study protocol was conducted in accordance with the
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA), Central Government of India
and the Institutional Animal Ethics Committee of Jadavpur
University, Kolkata. A total of 18 rats were divided into three
equal groups and following an overnight fast (18 h) were given a
single intraperitoneal (i.p.) injection of streptozotocin (STZ)
(65 mg/kg) dissolved in PBS pH 7.4 to induce diabetes. Diabetes
was veriﬁed 72 h later by evaluating blood glucose levels using a
one-touch glucometer (Accuchek); rats showing blood glucose
4250 mg/dL were considered to be diabetic and used in the study.
Group I was diabetic control, Group II was given an oral dose of
NTG 15 mg/kg as Glinate™ 60 and Group III (Test) was given an
oral dose of 15 mg/kg NTG as provesicular formulation F4. Blood
samples were collected from the retro orbital plexus prior to the dose
and after 1, 2, 4, 8, 12, 18 and 24 h. Blood glucose was determined
immediately using the one-touch glucometer.2.9. Statistical analysis
Statistical analysis of differences was carried out by one way
ANOVA and Student's t-test using Origin Pro 8.0 (Origin Lab
Corporation, Northampton, USA). Data are reported as mean7SD.
Differences for which Po0.05 were considered statistically signiﬁcant.3. Results
3.1. Morphology
FESEM images of pure NTG, blank and the F4 formulation are
shown in Fig. 1. The niosome size distribution was in the range
260–410 nm. The average diameter of the niosomes correlated
well with values obtained by DLS.3.2. EE and VS
EE of NTG provesicular powders is given in Table 1. Fig. 2D
represents the intensitysize distribution histogram of provesicu-
lar formulations as obtained from DLS measurements at
25.070.1 1C. The mean VS of formulations with NTG molar
ratios from 9:1 to 1:9 was found to be between 260 and 410 nm
indicating all have narrow size distributions.3.3. Osmotic shock studies
The effects of osmotic shock on provesicular formulations are
presented in Table 2. It was found that shrinkage occurred for all
formulations incubated in hypertonic medium whereas an increase
in VS occurred in hypotonic medium. When incubated in normal
saline (0.9% NaCl), formulations showed a small increase in VS.
Figure 1 Field emission scanning electron microscopy (FESEM) images of (a) nateglinide, (b) the blank formulation and (c) formulation F4 at
different scales.
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FTIR spectra of pure NTG, blank and the F4 formulation (Fig. 2A)
were very similar indicating that no signiﬁcant interaction occurred
between NTG and the other excipients.
3.5. DSC
DSC data (Fig. 2C) reveal that pure NTG shows a sharp
endothermic peak at 132.10 1C corresponding to its melting point.
Thermographs of the other two formulations show only slight
differences in the endothermic peak of NTG suggesting that no
signiﬁcant interaction occurs between NTG and the other con-
stituents of the formulations.
3.6. XRD
XRD patterns are presented in Fig. 2B. Pure NTG exhibited a
strong and characteristic XRD pattern consistent with a crystalline
powder whereas the blank and formulation F4 showed loss of
peaks and more diffuse peaks indicative of an amorphous form
of NTG.
3.7. In vitro release study
The in vitro release proﬁles of NTG from the provesicular
formulations and pure NTG are shown in Fig. 3. It was found
that provesicular formulation F4 (SP:CH molar ratio 5:5) exhibited
the highest rate of dissolution of NTG in both PBS pH 7.4 and
HCl (pH 1.2).
3.8. Goat intestine permeation study
The permeation of NTG from the three formulations as shown in
Fig. 4 reveals that formulation F4 gives the greatest permeation of
NTG through goat intestine followed by Glinate™ 60 and control
(Table 3). This may be due to the ability of the non-ionic
surfactant to act as a penetration enhancer through the gut wall.
3.9. Pharmacodynamic study
The hypoglycemic activity of the three formulations in STZ-
induced diabetic rats is shown in Fig. 5. It was observed that
formulation F4 produced a signiﬁcant reduction in blood glucose
levels compared to Glinate™ 60 (Po0.05) over 24 h.3.10. Stability study
Fig. 6 shows the results of stability testing of formulation F4
stored under refrigeration and at room temperature for three
months. Fig. 6C shows that the retention of NTG (%) in
formulation F4 was relatively unchanged under refrigerated
conditions for up to 3 months (Po0.05).4. Discussion
The size and diameter of the vesicles observed by FESEM were
found to correlate well with corresponding values obtained by
DLS measurements. FESEM images of formulation F4 showed
distinct spheres with smooth surfaces and revealed the absence of
native crystals of NTG in the provesicular powders. The change
from a highly porous surface in the blank to a plain surface in
formulation F4 undoubtedly indicates an efﬁcient drug loading of
NTG into the MLT matrix. In terms of the EE, it was found to be
in the range 66%–84% and to be signiﬁcantly higher in the
formulation with an SP:CH molar ratio of 5:5 (84.76%) than in the
other formulations (Po0.05). It was also found to increase as the
SP:CH molar ratio changed from 9:1 to 5:5 suggesting that
niosomes with relatively higher CH content have reduced bilayer
permeability to NTG38. However, when the SP:CH molar ratio
changed from 4:6 to 1:9, it resulted in a signiﬁcant decrease in EE
suggesting that the CH content beyond a certain level led to
disruption of the bilayer structure12,39.
Vesicles produced from provesicular formulations were found
to have VS in the range 260–410 nm (Fig. 2D) and to be nega-
tively charged as reﬂected in the zeta potentials (E45 mV)40.
Moreover, vesicles produced from formulation F4 were found to
have PIo0.3 indicating a homogeneous and monodisperse dis-
tribution of colloidal vesicles. DLS measurements also showed a
narrow size distribution further supporting an almost uniform
distribution of provesicle-derived niosomes. VS was found to be
inversely proportional to EE.
The FTIR spectrum of pure NTG showed an intense peak at
3356 cm1 assigned to –NH stretching. Another three distinct
peaks were observed at 1600 cm1, 1740 cm1 and 2861–
3063 cm1 assigned to –CQO, –COOH and –CH stretching
vibrations, respectively. In terms of interaction between NTG and
excipients, these four peaks showed no tangible shift indicating the
absence of any interaction.
In the DSC proﬁles, pure NTG showed a sharp characteristic
endotherm at 132.10 1C equating to its melting point. However,
the DSC thermogram of formulation F4 showed a small blunt
Figure 2 (A) FTIR spectra, (B) XRD proﬁles and (C) DSC thermograms of (a) nateglinide (b) the blank formulation and (c) formulation F4.
(D) Size distribution intensity of provesicular formulations (F1–F7) (data are means7SD, n¼3).
Table 2 Effect of osmotic shock on nateglinide provesicular formulations.
Formulation Average vesicle size (nm) after incubation with
PBS pH 7.4 1 mol/L NaI 0.9% NaCl 0.5% NaCl
F1 364.9743.7 Shrunk 376.4731.3 412.7767.8
F2 405.1753.1 Shrunk 415.5735.7 566.1767.5
F3 382.6747.3 Shrunk 395.2779.7 476.5753.2
F4 262.4776.2 Shrunk 270.37108.4 309.57115.0
F5 333.2754.0 Shrunk 334.2768.1 476.0792.3
F6 374.8761.2 Shrunk 387.07116.5 398.3756.3
F7 331.1744.8 Shrunk 333.1773.1 562.0784.5
Data are expressed as means7SD, n¼3.
Figure 3 In vitro release proﬁle of nateglinide-loaded provesicle formulations in (A) PBS pH 7.4 and (B) HCl pH 1.2.
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from a change in NTG structure from a crystalline to an
amorphous form. This may lead to an increase in the dissolution
proﬁle of NTG41 because amorphous drug does not require energy
to break up the crystalline lattice42.
In terms of XRD data, the intensity of the diffraction pattern of
pure NTG was higher at 4.31, 13.91 and 20.11 over a diffraction
angle of 2θ indicating that it mainly exists as a crystalline material.
However, the diffractograms of the blank and formulation F4
showed some loss of peaks and more diffused peaks suggesting its
presence in an amorphous state. These results reveal that NTG
changes from a crystalline form to an amorphous form when
formulated in proniosomes consistent with DSC studies.
In the in vitro release study, values of drug release from the
formulation F4 with an SP:CH molar ratio of 5:5 were 93.32% and
66.20% in dissolution media with pH 7.4 and 1.2, respectively.
Compared to other provesicular formulations and control, for-
mulation F4 showed a signiﬁcant enhancement of NTG dissolution
and a higher EE (84.76%) in both dissolution media (Po0.05).
This may be due to enhancement of NTG solubility by the non-
ionic surfactant or to a change in NTG structure from the
crystalline to the amorphous form in provesicular formulations40.
In fact, all provesicular formulations exhibited signiﬁcantly higher
dissolution than control in both dissolution media.
In the goat intestinal permeation study, the mean cumulative
amount of drug permeated from formulation F4 at 48 h
(30995.08 mg) was signiﬁcantly higher (Po0.05) than from
Glinate™ 60 and control as reﬂected in its higher steady state
ﬂux (626.3 mg/cm2/h) and permeability coefﬁcient (62.63 cm/h).
Furthermore, the enhancement ratio of formulation F4 was doubleFigure 4 Permeation proﬁles of nateglinide through goat intestine
from formulation F4 in comparison with Glinate™ 60 and control
(data are means7SD, n¼3).
Table 3 Permeation parameters of nateglinide from formulation F4 in
intestine.
Formulation M (mg)a Jss (m
F4 30,9957117 626.3
Marketed 27,0617134 510.5
Control 22,5767192 433.0
M, cumulative amount of drug permeated in 48 h; Jss, steady state ﬂux; Er,
Po0.05.
aData are expressed as means7SD, n¼3.than that of control indicating that the order of increasing
permeation enhancement was F44Glinate™ 604control. In
summary, the permeability of NTG was signiﬁcantly enhanced
(Po0.05) through the provesicular approach suggesting that
provesicles might also enhance its oral bioavailability.
In the pharmacodynamic study, Fig. 5 shows that the groups of
STZ induced diabetic rats treated with formulation F4 (test group)
and Glinate™ 60 (standard group) both showed a signiﬁcant
(Po0.05) reduction in blood glucose levels at 4 h after the dose.
Subsequently the group treated with Glinate™ 60 showed
increasing blood glucose levels whereas the group treated with
formulation F4 showed gradually decreasing levels up to 18 h.
This difference was sufﬁcient for the blood glucose level in the
formulation F4 treated group to be signiﬁcantly less (Po0.05)
than in the Glinate™ 60 treated group.
In the stability study, provesicular formulations stored in the
refrigerator (2–8 1C) and at room temperature (2572 1C) for three
months showed no evidence of drug precipitation and retained
their loose and uniform appearance. However, after 3 months
formulation F4 was more stable under refrigerated conditions than
at room temperature. Moreover, in terms of drug retention, Fig. 6C
shows that the retention in formulation F4 is unchanged during
storage under refrigerated conditions for 3 months (Po0.05). In
summary, the results reveal that formulation F4 is more stable
under refrigerated conditions than at room temperature with the
ability to assign an extended shelf-life.comparison with GlinateTM 60 (Marketed) and control across goat
g/cm2/h)a Er Kp (cm/h)
72.5 1.44 62.63
72.1 1.17 51.05
73.7 – 43.30
enhancement ratio; and Kp, permeability coefﬁcient.
Figure 5 Effect of optimized formulation F4 (SP:CH molar ratio 5:5)
and Glinate™ 60 on blood glucose levels in streptozotocin-induced
diabetic rats (data are means7SD, n¼3).
Figure 6 (A) Change of drug entrapment efﬁciency (%), (B) vesicle
size (nm) and (C) retention (%) of NTG in formulation F4 upon
storage in the refrigerator and at room temperature for 3 months (data
are means7SD, n¼3).
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The results of the present study show that a provesicle formulation
of an NTG–MTL complex with SP and CH produced free ﬂowing,
homogeneous and smooth vesicles. Of a number of formulations
containing different SP:CH ratios, formulation F4 with an SP:CH
molar ratio of 5:5 provided the highest EE and stability and gave
signiﬁcantly higher release of NTG (Po0.05) in PBS pH 7.4 and
HCl (pH 1.2) than from pure NTG. Furthermore, in a goat
intestinal permeation study, formulation F4 gave signiﬁcantly
higher mean cumulative amount of drug permeated at 48 h than
Glinate™ 60 and control and, in a pharmacodynamic study,produced a signiﬁcantly greater reduction in blood glucose. It
appears likely that these NTG provesicles will give higher
bioavailability than pure NTG and provide a more effective
treatment for type II diabetes.
Acknowledgments
This work was ﬁnancially supported by the All India Council of
Technical Education (AICTE) India (Grant No. KLECOP/QIP/
2010). The authors are very grateful to Professor Amul Kumar
Bandyopadhyay of Jadavpur University, Kolkata, India, for his
fundamental support and useful discussions.
References
1. Manconi M, Sinico C, Donatella V, Loy G, Fadda AM. Niosomes as
carriers for tritenoin. I. Preparation and properties. Int J Pharm
2002;234:237–48.
2. Hu CJ, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int
J Pharm 1999;185:23–35.
3. Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH. In vitro skin
permeation of estradiol from various proniosome formulations. Int J
Pharm 2001;215:91–9.
4. Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. Design
and development of a proniosomal transdermal drug delivery system
for captopril. Trop J Pharm Res 2007;6:687–93.
5. Varshosaz J, Pardakhty A, Seied MHB. Sorbitan monopalmitate-based
proniosomes for transdermal delivery of chlorpheniramine maleate.
Drug Deliv 2005;12:75–82.
6. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery
of levonorgestrel for effective contraception. J Control Release
1998;54:149–65.
7. Renko M. Theoretical study of molecular structure, pKa, lipophilicity,
solubility, absorption, and polar surface area of some hypoglycemic
agents. J Mol Struct 2009;897:73–82.
8. Tang J, Sun J, He ZG. Self-emulsifying drug delivery systems: strategy
for improving oral delivery of poorly soluble drugs. Curr Drug Ther
2007;2:85–93.
9. Garnero C, Aloisio C, Longhi M. Ibuprofen-maltodextrin interaction:
study of enantiomeric recognition and complex characterization.
Pharmacol Pharmacy 2013;4:18–30.
10. Blazek-Welsh AI, Rhodes DG. Maltodextrin-based proniosomes.
Pharm Sci 2001;3:1–8.
11. Blazek-Welsh AI, Rhodes DG. SEM imaging predicts quality of
niosomes from maltodextrin-based proniosomes. Pharm Res 2001
656–61.
12. Hao Y, Zhao F, Li N, Yang Y, Li K. Studies on a high encapsulation
of colchicine by niosome system. Int J Pharm 2002;244:73–80.
13. Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and
evaluation of reverse-phase evaporation and multilamellar niosomes as
ophthalmic carriers of acetazolamide. Int J Pharm 2005;306:71–82.
14. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes)
in drug delivery. Int J Pharm 1998;172:33–70.
15. Kibbe AH. In: Handbook of pharmaceutical excipients. 3rd ed.
Washington, DC: American Pharmaceutical Association; 2000.
16. Yoshioka T, Sternberg B, Florence AT. Preparation and properties of
vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80)
and sorbitan trimester (Span 85). Int J Pharm 1994;105:1–6.
17. Verma S, Singh SK, Syan N, Mathus P, Valecha V. Nanoparticle
vesicular systems: a versatile tool for drug delivery. J Chem Pharm
Res 2010;2:496–509.
18. Girigoswami A, Das S, De S. Fluorescence and dynamic light
scattering studies of niosomes-membrane mimetic systems. Spectro-
chim Acta A 2006;64:859–66.
19. Rogerson A, Cummings J, Florence AT. Adriamycin-loaded niosomes:
drug entrapment, stability and release. J Microencapsul 1987;4:321–8.
Ranjan Ku. Sahoo et al.41620. Pasha SW, Madhu MVV, Bonthu S, Nagakanyaka DP, Rajeev KM,
Arief MD, et al. Evaluation of crystal forms of nateglinide. Int J Res
Pharm Sci 2013;4:427–37.
21. Leuner C, Dressman J. Improving drug solubility for oral delivery
using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60.
22. Loftsson T. Pharmaceutical Application of β-cyclodextrin. Pharm
Technol 1999;23:40–50.
23. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems.
Chem Rev 1998;98:2045–76.
24. He Z, Chen X, Zhong D, Zhao C, Liu X, Zhang R. Study on the
bioavailability of nateglinide-hydroxypropyl-beta-cyclodextrin com-
plex capsule in rabbits by liquid chromatographic-tandem mass
spectrometry. Biomed Chromatogr 2004;18:532–7.
25. Chaudhary A, Garud N, Garud A. Formulation and in-vitro character-
ization of ﬂoating drug delivery system of nateglinide. Am J
PharmTech Res 2013;3:479–86.
26. Rane BR, Gujarathi NA, Patel JK. Preparation and in-vitro character-
ization of ﬂoating microspheres of nateglinide. Int J Pharm Sci Res
2012;3:4306–13.
27. Kaleemuddin M, Srinivas P. Lyophilized oral sustained release
polymeric nanoparticles of nateglinide. AAPS PharmSciTech 2012
78–85.
28. Khemariya P, Jain A, goswami R, Bhargava M, Goswami S, Singhal
SK. Advances in novel drug delivery carriers: formulation and in vitro
of solid lipid nanoparticles of nateglinide. Int J Pharm Appl Sci
2010;1:104–7.
29. Sentjurc M, Vrhovnik K, Kristl J. Liposomes as a topical delivery
system: the role of size on transport studied by the EPR imaging
method. J Control Release 1999;59:87–97.
30. Centis V, Vermette P. Physico-chemical properties and cytotoxicity
assessment of PEG-modiﬁed liposomes containing human hemoglo-
bin. Colloids Surf B: Biointerfaces 2008;65:239–46.31. Deepika A, Indu PK. Improved pharmacodynamics of timolol maleate
from a mucoadhesive niosomal ophthalmic drug delivery system. Int J
Pharm 2005;290:155–9.
32. Vyas SP, Venkatesan N. Poly(phthaloyl-L-lysine)-coated multilamellar
vesicles for controlled drug delivery: in vitro and in vivo performance
evaluation. Pharm Acta Helv 1999;74:51–8.
33. Ruckmani K, Sankar V. Formulation and optimization of zidovudine
niosomes. AAPS PharmSciTech 2010;11:1119–27.
34. Higuchi TJ. Mechanism of sustained-action medication. Theoretical
analysis of rate of release of solid drugs dispersed in solid matrices. J
Pharm Sci 1963;52:1145–9.
35. Tavano L, Alfano P, Muzzalupo R, Cindio BD. Niosomes vs
microemulsions: new carriers for topical delivery of capsaicin.
Colloids Surf B: Biointerfaces 2011;87:333–9.
36. Higashiyama M, Inada K, Ohtori A, Tojo K. Improvement of the
ocular bioavailability of timolol by sorbic acid. Int J Pharm 2004;272:
91–8.
37. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of
polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J
Pharm 2007;328:130–41.
38. Chandra A, Sharma PK. Proniosome based drug delivery system of
piroxicam. Afr J Pharm Pharmacol 2008;2:184–90.
39. Bernsdorff C, Wolff A, Winter R, Gratton E. Effect of hydrostatic
pressure on water penetration and rotational dynamics in phospholi-
pid–cholesterol bilayers. Biophys J 1997;72:1264–77.
40. Di Marzio L, Marianecci C, Petrone M, Rinaldi F, Carafa M. Novel
pH-sensitive non-ionic surfactant vesicles: comparison between Tween
21 and Tween 20. Colloids Surf B: Biointerfaces 2011;82:18–24.
41. Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane
for improved oral delivery: formulation and in vitro evaluation using
PAMPA, Caco-2 and rat intestine. Int J Pharm 2009;380:96–104.
42. Hancock BC, Zograﬁ G. Characteristics and signiﬁcance of the amor-
phous state in pharmaceutical systems. J Pharm Sci 1997;86:1–12.
